NBI 1065890
Alternative Names: NBI-1065890; NBI-890Latest Information Update: 30 Jan 2026
At a glance
- Originator Neurocrine Biosciences
- Class Antipsychotics; Small molecules
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Schizophrenia
Highest Development Phases
- Phase II Tardive dyskinesia
- Preclinical Neurological disorders; Psychiatric disorders
Most Recent Events
- 26 Jan 2026 Phase-II clinical trials in Tardive dyskinesia (PO) (NCT07365462) (CTIS-2025-524104-30-00)
- 28 Mar 2024 Phase-I clinical trials in Neurological disorders (In volunteers) (PO)
- 11 Dec 2023 NBI 1065890 is available for licensing as of 11 Dec 2023. https://www.neurocrine.com/pipeline/ (Neurocrine Biosciences website, December 2023)